← Back to Search

Glaucoma Implant

AqueSys XEN 45 Glaucoma Implant for Glaucoma

N/A
Waitlist Available
Research Sponsored by AqueSys, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.

Eligible Conditions
  • Glaucoma
  • Open-Angle Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Change in IOP From Baseline
Proportion of Subjects Achieving a 20% or Greater Reduction in IOP From Baseline on the Same or Less Number of Medications

Trial Design

1Treatment groups
Experimental Treatment
Group I: AqueSys XEN 45 Glaucoma ImplantExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AqueSys XEN 45 Glaucoma Implant
2013
N/A
~70

Find a Location

Who is running the clinical trial?

AqueSys, Inc.Lead Sponsor
2 Previous Clinical Trials
259 Total Patients Enrolled
2 Trials studying Glaucoma
259 Patients Enrolled for Glaucoma
AllerganIndustry Sponsor
781 Previous Clinical Trials
276,766 Total Patients Enrolled
91 Trials studying Glaucoma
49,051 Patients Enrolled for Glaucoma
Richard A Lewis, M.D.Study ChairGrutzmacher, Lewis & Sierra Surgical Eye Specialists
1 Previous Clinical Trials
60 Total Patients Enrolled
1 Trials studying Glaucoma
60 Patients Enrolled for Glaucoma
~5 spots leftby Jun 2025